Literature DB >> 11771741

Alteration of caspases and other apoptosis regulatory proteins in Down syndrome.

T Gulesserian1, E Engidawork, B C Yoo, N Cairns, G Lubec.   

Abstract

Apoptosis has been implicated in the selective neuronal loss of Down syndrome (DS). Apoptosis activates a family of cysteine proteases with specificity for aspartic acid residues referred to as caspases that play a key role in dismantling a cell committed to die. Caspase activity is regulated by a variety of proteins that possess a domain resembling the prodomains of caspases. Little is known, however, about the changes of caspases and their regulatory proteins in DS. Here, we investigated levels of nine such different proteins by western blot technique in frontal cortex and cerebellum of control and DS subjects. The protein levels of DFF45 (DNA fragmentation factor 45), and FLIP (FADD like interleukin-1beta-converting enzyme inhibitory proteins) were significantly decreased whereas that of RICK (RIP-like interacting CLARP kinase) increased in both regions of DS. In contrast, cytochrome c, Apaf-1 (apoptosis protease activating factor-1), procaspase-9 and ARC (apoptosis repressor with caspase recruitment domain) were unchanged. Procaspase-3 and -8 were significantly decreased in frontal cortex but no significant change was observed in cerebellum. Regression analysis revealed no correlation between postmortem interval and levels of the investigated proteins. However, inconsistent correlation was found between age and levels of proteins as well as amongst the density of individual proteins. These findings demonstrate that dysregulation of apoptotic proteins does exist in DS brain and may underlie the neuropathology of DS. The study further suggests that apoptosis in DS may occur via the death receptor pathway independent of cytochrome c. Hence, therapeutic strategies that target caspase activation may prove useful in combating neuronal loss in this disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11771741     DOI: 10.1007/978-3-7091-6262-0_13

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  6 in total

1.  Expression of LDOC1 mRNA in leucocytes of patients with Down's syndrome.

Authors:  Michele Salemi; Concetta Barone; Carmelo Romano; Federico Ridolfo; Roberto Salluzzo; Francesco Scillato; Cataldo Scavuzzo; Filippo Caraci; Aldo E Calogero; Corrado Romano; Paolo Bosco
Journal:  J Genet       Date:  2012       Impact factor: 1.166

Review 2.  Aberrant expression of RCAN1 in Alzheimer's pathogenesis: a new molecular mechanism and a novel drug target.

Authors:  Yili Wu; Philip T T Ly; Weihong Song
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

3.  Gene expression analysis of cultured amniotic fluid cell with Down syndrome by DNA microarray.

Authors:  In-Hyuk Chung; Sook-Hwan Lee; Kyo-Won Lee; Sang-hee Park; Kwang-Yul Cha; Nam-Soon Kim; Hyang-Sook Yoo; Yong Sung Kim; Suman Lee
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

Review 4.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

5.  The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts.

Authors:  Sylwia Dragojew; Agnieszka Marczak; Janusz Maszewski; Krzysztof Ilnicki; Zofia Jóźwiak
Journal:  Cell Mol Biol Lett       Date:  2008-04-10       Impact factor: 5.787

6.  Familial cortical myoclonus with a mutation in NOL3.

Authors:  Jonathan F Russell; Jamie L Steckley; Giovanni Coppola; Angelika F G Hahn; MacKenzie A Howard; Zachary Kornberg; Alden Huang; Seyed M Mirsattari; Barry Merriman; Eric Klein; Murim Choi; Hsien-Yang Lee; Andrew Kirk; Carol Nelson-Williams; Gillian Gibson; Scott C Baraban; Richard P Lifton; Daniel H Geschwind; Ying-Hui Fu; Louis J Ptáček
Journal:  Ann Neurol       Date:  2012-08       Impact factor: 10.422

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.